New International Guidelines and Consensus on the Use of Lung Ultrasound.

Following the innovations and new discoveries of the last 10 years in the field of lung ultrasound (LUS), a multidisciplinary panel of international LUS experts from six countries and from different fields (clinical and technical) reviewed and updated the original international consensus for point-of-care LUS, dated 2012. As a result, a total of 20 statements have been produced. Each statement is complemented by guidelines and future developments proposals. The statements are furthermore classified based on their nature as technical (5), clinical (11), educational (3), and safety (1) statements.

Bridging the Gap Between Competencies and Uncertainties in Postgraduate Training in Family Medicine: Results and Psychometric Properties of a Self-Assessment Questionnaire.

Purpose: One of the reasons for postgraduate trainees not to choose working in a rural area is uncertainty related to the lack of competencies. The aim of this study was to investigate the concept of uncertainty by measuring competencies and to examine the psychometric properties of an instrument that measures competencies related to uncertainty in the self-assessment of postgraduate trainees in family medicine. Patients and Methods: A questionnaire was created based on pre-existing instruments. It was distributed to participants of postgraduate training seminars in the federal states of Baden-Württemberg and Schleswig-Holstein, Germany in 2016. Descriptive statistics and a partial correlation analysis were calculated for measuring the degree of association between year of postgraduate training and items' responses. Psychometric properties were assessed by calculating descriptive item analysis, factor analysis and internal consistency. Results: The response rate was 85% (105/124). More than one-fifth of the participants stated to show only seldom or sometimes the following skills: ability to balance work and life (N=25, 24%), letting a mild disorder run its own way (N=24, 23%) and ability to conduct interventions that decreased aggression from the patient (N=22, 21%). More than half of the participants felt (very) insecure in performing routine child check-ups, the application of a below elbow backslab and the partial removal of a toenail. Nine out of 21 items showed positive statistically significant correlation between level of competence and progress in training. Factor analysis led to a final instrument with 12 items (Cronbach's α=0.736) and a three-factor-structure: "doctor well-being and resilience", "communication" and "skills". Conclusion: In order to reduce uncertainty with all its consequences, a focus on teaching of competencies regarding the physicians' well-being and resilience, communication and skills has to be continued in postgraduate training.

Investigating training-test data splitting strategies for automated segmentation and scoring of COVID-19 lung ultrasound images.

Ultrasound in point-of-care lung assessment is becoming increasingly relevant. This is further reinforced in the context of the COVID-19 pandemic, where rapid decisions on the lung state must be made for staging and monitoring purposes. The lung structural changes due to severe COVID-19 modify the way ultrasound propagates in the parenchyma. This is reflected by changes in the appearance of the lung ultrasound images. In abnormal lungs, vertical artifacts known as B-lines appear and can evolve into white lung patterns in the more severe cases. Currently, these artifacts are assessed by trained physicians, and the diagnosis is qualitative and operator dependent. In this article, an automatic segmentation method using a convolutional neural network is proposed to automatically stage the progression of the disease. 1863 B-mode images from 203 videos obtained from 14 asymptomatic individual,14 confirmed COVID-19 cases, and 4 suspected COVID-19 cases were used. Signs of lung damage, such as the presence and extent of B-lines and white lung areas, are manually segmented and scored from zero to three (most severe). These manually scored images are considered as ground truth. Different test-training strategies are evaluated in this study. The results shed light on the efficient approaches and common challenges associated with automatic segmentation methods.

Introduction to the special issue on lung ultrasound.

The potential of lung ultrasound (LUS) has become manifest in the light of the recent COVID-19 pandemic. The need for a point-of care, quantitative, and widely available assessment of lung condition is critical. However, conventional ultrasound imaging was never designed for lung assessment. This limits LUS to the subjective and qualitative interpretation of artifacts and imaging patterns visible on ultrasound images. A number of research groups have begun to tackle this limitation, and this special issue reports on their most recent findings. Through in silico, in vitro, and in vivo studies (preclinical animal studies and pilot clinical studies on human subjects), the research presented aims at understanding and modelling the physical phenomena involved in ultrasound propagation, and at leveraging these phenomena to extract semi-quantitative and quantitative information relevant to estimate changes in lung structure. These studies are the first steps in unlocking the full potential of lung ultrasound as a relevant tool for lung assessment.

Impact of intravenous lidocaine on clinical outcomes of patients with ARDS during COVID-19 pandemia (LidoCovid): A structured summary of a study protocol for a randomised controlled trial.

OBJECTIVES: The main objective of this study is to evaluate the effect of intravenous lidocaine on gas exchange and inflammation in acute respiratory distress syndrome due or not to Covid-19 pneumonia. TRIAL DESIGN: This is a prospective monocentric, randomized, quadruple-blinded and placebo-controlled superiority trial. This phase 3 clinical study is based on two parallel groups received either intravenous lidocaine 2% or intravenous NaCl 0.9%. PARTICIPANTS: This study has been conducted at the University Hospitals of Strasbourg (medical and surgical Intensive Care Units in Hautepierre Hospital) since the 4th November 2020. The participants are 18 years-old and older, hospitalized in ICU for a moderate to severe ARDS according to the Berlin definition; they have to be intubated and sedated for mechanical protective ventilation. All participants are affiliated to the French Social security system and a dosage of beta HCG has to be negative for women of child bearing age . For the Covid-19 subgroup, the SARS-CoV2 infection is proved by RT-PCR <7 days before admission and/or another approved diagnostic technique and/or typical CT appearance pneumonia. The data are prospectively collected in e-Case Report Forms and extracted from clinical files. INTERVENTION AND COMPARATOR: The participants are randomised in two parallel groups with a 1:1 ratio. In the experimental group, patients receive intravenous lidocaine 2% (20mg/mL) (from FRESENIUS KABI France); the infusion protocol provide a bolus of 1 mg/kg (ideal weight), followed by 3 mg/kg/h for the first hour, 1.5 mg/kg/h for the second hour, 0.72 mg/kg/h for the next 22 hours and then 0.6 mg/kg/h for 14 days at most or 24 hours after extubation or ventilator-weaning. The patients in the control group receive intravenous NaCl 0.9% (9 mg/mL) (from Aguettant, France) as placebo comparator; the infusion protocol provide a bolus of 0.05 mL/kg (ideal weight), followed by 0.15 mL/kg/h for the first hour, 0.075 mL/kg/h for the second hour, 0.036 mL/kg/h for the next 22 hours, and the 0.03 mL/kg/h for up to 14 days or 24 hours after extubation or ventilator-weaning. Lidocaine level is assessed at H4, D2, D7 and D14 to prevent local anesthetics systemic toxicity. Clinical data and biological samples are collected to assess disease progression. MAIN OUTCOMES: The primary outcome is the evolution of alveolar-capillary gas exchange measured by the PaO2/FiO2 ratio after two days of treatment. The secondary endpoints of the study include the following: Evolution of PaO2/FiO2 ratio at admission and after 21 days of treatment Number of ventilator-free days Anti-inflammatory effects by dosing inflammatory markers at different timepoints (ferritin, bicarbonate, CRP, PCT, LDH, IL-6, Troponin HS, triglycerides, complete blood count, lymphocytes) Anti-thrombotic effects by dosing platelets, aPTT, fibrinogen, D-dimers, viscoelastic testing and identification of all thromboembolic events up to 4 weeks. Plasmatic concentration of lidocaine and albumin Incidence of adverse events like cardiac rhythm disorders, need of vasopressors, any modification of the QRS, QTc or PR intervals every day Ileus recovery time Consumption of hypnotics, opioids, neuromuscular blockers. Lengths of stay in the ICU, incidence of reintubation and complications due to intensive care unit care (mortality until 90 days, pneumothorax, bacterial pneumopathy, bronchospasm, cardiogenic shock, acute renal failure, need of renal dialysis, delirium, atrial fibrillation, stroke (CAM-ICU score), tetraplegia (MCR score)). Incidence of cough and sore throat at extubation or ventilator-weaning and within 24 hours. All these outcomes will be evaluated according to positivity to Sars-Cov-2. RANDOMISATION: The participants who meet the inclusion criteria and have signed written informed consent will be randomly allocated using a computer-generated random number to either intervention group or control group. The distribution ratio of the two groups will be 1:1, with a stratification according to positivity to Sars-Cov-2. BLINDING (MASKING): All participants, care providers, investigator and outcomes assessor are blinded. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): We planned to randomize fifty participants in each group, 100 participants total. TRIAL STATUS: The amended protocol version 2.1 was approved by the Ethics Committee "Comité de Protection des Personnes Sud-Méditerranée II on January 8, 2021 and by the Commission Nationale de l'Informatique et des Libertés (CNIL) on November 10, 2020. The study is currently recruiting participants; the recruitment started in November 2020 and the planned recruitment period is three years. TRIAL REGISTRATION: The trial was registered on clinicaltrials.gov on October 30, 2020 and identified by number NCT04609865 . FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

COVID-19 Risks Outlook: A Preliminary Mapping and Its Implications

From the Introduction: The first global pandemic in over 100 years, COVID-19 [coronavirus disease 2019] spread across the world at an unprecedented speed. [...] As countries seek to recover, some of the more lasting economic, environmental, societal and technological challenges and opportunities are only beginning to become visible. While societies, governments and businesses collectively grapple with these possibilities, it is vital to anticipate the emerging risks generated by the repercussions from the pandemic. 'The COVID-19 Risks Outlook' seeks to provide a preliminary picture of which familiar risks may be amplified by the crisis and which new ones may emerge, recognizing that key issues remain to be analysed - health and geopolitics among them. This report is an initial mapping that will be supplemented by further work including the World Economic Forum's annual 'Global Risks Report.'COVID-19 (Disease);World health;Risk assessment

Challenges and Opportunities in the Post-COVID-19 World

From the Introduction: While a global pandemic has been a looming risk for decades, COVID-19 [coronavirus disease 2019] has come as a shock to society, health systems, economies and governments worldwide. In the midst of extraordinary challenges and uncertainty, and countless personal tragedies, leaders are under pressure to make decisions on managing the immediate impact of the pandemic and its consequences, decisions that will shape the state of the world for years to come. What might be the silver linings in the crisis and how might leaders use this moment to build a more prosperous, equitable and sustainable world? In this collection of essays, the Global Risks Advisory Board of the World Economic Forum's Global Risks Initiative looks beyond the current crisis to the potential challenges and opportunities in the post-COVID-19 world. The result is a range of expert opinions from a geographically diverse set of leaders. They are designed to offer new perspectives on the post-pandemic future, in support of efforts to proactively and collectively shape the future we want.COVID-19 (Disease);Risk assessment;World health